Physician profile
Bernard D Morris
NPI 1598703720
$7,106.54
in general payments reported to CMS, 2019-2025
28 companies · $364 in 2025
The $364 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.09 · 2020: $166 · 2021: $223 · 2022: $694 · 2023: $540 · 2024: $5,031 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $1,717 · Travel and Lodging: $1,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $1,716.95 |
| Travel and Lodging | $1,218.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,434.23 | 2024 | |
| Teleflex LLC | $834.37 | 2021-2025 | Urolift, Barrigel |
| Abbvie INC. | $400.83 | 2019-2024 | |
| Boston Scientific Corporation | $146.11 | 2022-2024 | Rezum Generator |
| Inspire Medical Systems, INC. | $145.67 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $144.22 | 2023-2024 | Gemtesa |
| Blue Earth Diagnostics | $133.84 | 2024 | |
| Axonics, INC. | $121.09 | 2020-2024 | Axonics |
| Abbott Laboratories | $102.97 | 2024 | Eterna, Proclaim |
| Urovant Sciences INC | $100.33 | 2021-2022 | |
| Coloplast Corp | $67.06 | 2022 | |
| Allergan, INC. | $65.58 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $54.85 | 2019-2020 | |
| Astellas Pharma US INC | $47.38 | 2019-2021 | |
| Myovant Sciences INC. | $40.17 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hollister Incorporated | $35.25 | 2024 | Vapro Pocket |
| Caldera Medical, INC | $28.05 | 2021-2023 | Desara |
| Endo Pharmaceuticals INC. | $26.29 | 2020-2021 | |
| Dendreon Pharmaceuticals LLC | $24.00 | 2024 | Provenge |
| Olympus America INC. | $23.13 | 2023 | Olympus, Soltive |
| Menarini Silicon Biosystems, INC. | $20.01 | 2023 | Cellsearch |
| Kowa Pharmaceuticals America, INC. | $18.82 | 2023 | Seglentis |
| Neotract INC. | $18.70 | 2020 | |
| Urogen Pharma, INC. | $16.81 | 2022 | |
| Antares Pharma, INC. | $16.73 | 2022 | |
| Laborie Medical Technologies Corp. | $14.34 | 2020 | |
| 180 Medical, INC. | $14.21 | 2022 | |
| Pfizer INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.